Matthew Roh, MD
Physical Medicine & Rehabilitation · Waldorf, MDNPI 1871807818
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 93 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 18.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $712 and has fallen 95.9% since, to $29 in 2025.
Across 93 payments — averaging $21.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$368
- AbbVie$222
- Collegium Pharmaceutical, Inc.$193
- Boston Scientific$191
- Scilex Pharmaceuticals Inc.$128
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$110
- plus $763 from 16 others
What the payments were for
- Food & beverage$1,976100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 11 | $368 |
| AbbVie(2 entities) | 10 | $222 |
| Collegium Pharmaceutical, Inc. | 10 | $193 |
| Boston Scientific | 9 | $191 |
| Scilex Pharmaceuticals Inc. | 7 | $128 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $110 |
| MDD US Operations, LLC | 5 | $108 |
| Si-bone, Inc. | 4 | $105 |
| Biodelivery Sciences International, Inc. | 5 | $89 |
| DJO, LLC | 1 | $83 |
| Pfizer | 5 | $72 |
| Indivior Inc. | 4 | $55 |
| Sentynl Therapeutics, Inc. | 3 | $48 |
| ERMI LLC | 2 | $31 |
| Medtronic | 2 | $30 |
| Electronic Waveform Lab, Inc. | 1 | $29 |
| Johnson & Johnson | 1 | $28 |
| Nevro Corp. | 1 | $23 |
| Protega Pharmaceutials Inc | 1 | $18 |
| Kaleo, Inc. | 1 | $18 |
| Orexo US, Inc. | 1 | $14 |
| Redhill Biopharma Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,976 in reported general payments places this provider in the 80th percentile of 202 physical medicine & rehabilitation providers in Maryland.
See all physical medicine & rehabilitation providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 242 | $161,767 |
| Xtampza ErOxycodone Myristate | 104 | $49,995 |
| NucyntaTapentadol Hcl | 20 | $22,003 |
| Fentanyl | 147 | $21,160 |
| Oxycodone Hcl | 890 | $19,841 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 389 | $11,334 |
| Morphine Sulfate ErMorphine Sulfate | 402 | $9,074 |
| Lidocaine | 82 | $8,131 |
| MovantikNaloxegol Oxalate | 17 | $6,716 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 40 | $5,460 |
| SymproicNaldemedine Tosylate | 12 | $5,336 |
| Gabapentin | 355 | $4,178 |
| Naloxone Hcl | 36 | $3,293 |
| Hydromorphone ErHydromorphone Hcl | 22 | $2,987 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 98 | $2,835 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er, Nucynta | $193 | $71,998124 claims |
| Redhill Biopharma Inc.Movantik | $12 | $6,71617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 202 physical medicine & rehabilitation providers in Maryland.
Other physical medicine & rehabilitation in Waldorf
- David RodriguezWaldorf$5K
- David ReeceBethesda$719K
- Gurtej SinghCatonsville$205K
- Akhil ChhatreBaltimore$169K
- Justin WassermanBethesda$51K
- Vivek SindhiGlen Burnie$33K
- Inai MkandawireOwings Mills$23K
- Cheryl MejiaHagerstown$20K
- Ronald ShinBaltimore$19K
- Mustafa BroachwalaBaltimore$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.